Figure 9.

In situ nanomedicine for fluorescent imaging contrast. A photo of a mouse with A) a subcutaneous hepatocellular carcinoma and B) in vivo fluorescence image of intratumorally generated fluorescent GNCs, 24 h after a subcutaneous injection of 10 mm HAuCl₄. C) In vivo fluorescence image of chronic myeloid leukemia 24 h after 10 mm injection of HAuCl₄ near the tumor. D) In vivo fluorescence image of a control (non‐tumor bearing) mouse 48 h after 10 mm injection of HAuCl₄ in the right side of the abdomen. E) Bright field and in vivo fluorescence images xenograft tumors treated either with mixtures of 7.5 mm Au³⁺ with PEG (Au‐PEG) or the same molar concentration of sodium chloride PEG mixture (Na‐PEG, control); the top and the middle images show intratumoral injections and the bottom images are from a transdermal injection (administered locoregionally to the tumor). F) Longitudinal assessment of fluorescence contrast comparing intratumoral and intradermal injections of ionic gold (Au‐PEG) and salt control (Na‐PEG) in mice that were used in photothermal therapy study (“+/‐“ indicates whether a laser was applied during treatment). A–D) Reproduced under the terms of a Creative Commons Attribution 4.0 International License.^{[ 28e ]} Copyright 2013, Springer Nature. E,F) Reproduced under the terms of a Creative Commons Attribution 4.0 International License.^{[ 28b ]} Copyright 2020, Springer Nature.